Mesothelioma Cancer Centers

Thoracic oncology specialists at the Barbara Ann Karmanos Cancer Institute at Wayne State University offers multidisciplinary treatment for mesothelioma patients. Their team works to provide customized treatment to patients based on their individual needs.

The institute goes beyond their collaborative team of oncologists, surgeons, radiologists and pathologists and also devotes time to research processes for early detection of precancerous cells to provide mesothelioma and lung cancer diagnoses in their early stages. They also study new and advanced treatment options for mesothelioma and cancers of the chest. The thoracic oncology team specializes in different forms of radiation therapy, including intensive modulated radiation therapy (IMRT), stereotactic body radiation therapy and gamma knife radiation for metastatic cancers. The department also frequently leads clinical trials and collaborates with others in the center’s Phase I Clinical Trials Program. This gives patients the opportunity to participate in clinical trials and work with the team to identify the best method of treatment.

Supportive oncology is also offered at the institute, providing symptom control, pain management and other alternative treatment needs in order to improve the quality of life for patients during their treatment.

Specializations:

• Chemotherapy
• Immunotherapy
• Minimally invasive surgery
• Radiation therapy

Accreditations:

• National Cancer Institute (NCI) Comprehensive Care Center
• ACR Designated Lung Cancer Screening Program
• Member of the Michigan Cancer Consortium

Mesothelioma Clinical Trials at Barbara Ann Karmanos Cancer Institute

The following clinical trials are in progress or actively recruiting participants at Barbara Ann Karmanos Cancer Institute:

• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

  Conditions:	Mesothelioma
  Last Updated:	July 1, 2019
  Status:	Active, not recruiting

• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

  Conditions:	Advanced Malignancies
  Last Updated:	April 26, 2019
  Status:	Active, not recruiting

Sources